310 related articles for article (PubMed ID: 33012018)
1. Upregulation of the long noncoding RNAs DSCAM-AS1 and MANCR is a potential diagnostic marker for breast carcinoma.
Tahmouresi F; Razmara E; Pakravan K; Mossahebi-Mohammadi M; Rouhollah F; Montazeri M; Sarrafzadeh A; Fahimi H; Babashah S
Biotechnol Appl Biochem; 2021 Dec; 68(6):1250-1256. PubMed ID: 33012018
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of circulating DSCAM-AS1 in patients with ER-positive breast cancer and construction of its competitive endogenous RNA network.
Moradi MT; Fallahi H; Rahimi Z
Mol Biol Rep; 2020 Oct; 47(10):7685-7697. PubMed ID: 33040318
[TBL] [Abstract][Full Text] [Related]
3. DSCAM-AS1 promotes tumor growth of breast cancer by reducing miR-204-5p and up-regulating RRM2.
Liang WH; Li N; Yuan ZQ; Qian XL; Wang ZH
Mol Carcinog; 2019 Apr; 58(4):461-473. PubMed ID: 30457164
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer.
Tarighi M; Khalaj-Kondori M; Hosseinzadeh A; Abtin M
Breast Dis; 2021; 40(2):63-68. PubMed ID: 33554879
[TBL] [Abstract][Full Text] [Related]
5. DSCAM-AS1 up-regulation in invasive ductal carcinoma of breast and assessment of its potential as a diagnostic biomarker.
Khorshidi H; Azari I; Oskooei VK; Taheri M; Ghafouri-Fard S
Breast Dis; 2019; 38(1):25-30. PubMed ID: 30594914
[TBL] [Abstract][Full Text] [Related]
6. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
7. LncRNA ST8SIA6-AS1 promotes proliferation, migration and invasion in breast cancer through the p38 MAPK signalling pathway.
Fang K; Hu C; Zhang X; Hou Y; Gao D; Guo Z; Li L
Carcinogenesis; 2020 Sep; 41(9):1273-1281. PubMed ID: 31784750
[TBL] [Abstract][Full Text] [Related]
8. LncRNA DSCAM-AS1: A Pivotal Therapeutic Target in Cancer.
Hu C
Mini Rev Med Chem; 2023; 23(5):530-536. PubMed ID: 35996247
[TBL] [Abstract][Full Text] [Related]
9. The potential roles of lncRNAs DUXAP8, LINC00963, and FOXD2-AS1 in luminal breast cancer based on expression analysis and bioinformatic approaches.
Arabpour M; Layeghi SM; Bazzaz JT; Naghizadeh MM; Majidzadeh-A K; Shakoori A
Hum Cell; 2021 Jul; 34(4):1227-1243. PubMed ID: 34043149
[TBL] [Abstract][Full Text] [Related]
10. The Expression Patterns and Implications of
Syllaios A; Gazouli M; Vailas M; Mylonas KS; Sakellariou S; Sougioultzis S; Karavokyros I; Liakakos T; Schizas D
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203269
[TBL] [Abstract][Full Text] [Related]
11. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136.
Huang YL; Xu Q; Wang X
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):2888-2897. PubMed ID: 31002140
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA DSCAM-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in ovarian cancer via upregulating SOX4.
Li Y; Hao J; Jiang YM; Liu Y; Zhang SH
Eur Rev Med Pharmacol Sci; 2019 May; 23(10):4143-4148. PubMed ID: 31173284
[TBL] [Abstract][Full Text] [Related]
14. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.
Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G
Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Expression of
Rishehri M; Etemadi T; Pisheh L; Koufigar G; Azadeh M
Genet Res (Camb); 2022; 2022():6787791. PubMed ID: 36160032
[TBL] [Abstract][Full Text] [Related]
16. Mitotically-Associated lncRNA (MANCR) Affects Genomic Stability and Cell Division in Aggressive Breast Cancer.
Tracy KM; Tye CE; Ghule PN; Malaby HLH; Stumpff J; Stein JL; Stein GS; Lian JB
Mol Cancer Res; 2018 Apr; 16(4):587-598. PubMed ID: 29378907
[TBL] [Abstract][Full Text] [Related]
17. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA DSCAM-AS1 functions as an oncogene in non-small cell lung cancer by targeting BCL11A.
Liao J; Xie N
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1087-1092. PubMed ID: 30779076
[TBL] [Abstract][Full Text] [Related]
19. DSCAM-AS1 mediates pro-hypertrophy role of GRK2 in cardiac hypertrophy aggravation via absorbing miR-188-5p.
Chen H; Cai K
In Vitro Cell Dev Biol Anim; 2020 Apr; 56(4):286-295. PubMed ID: 32377998
[TBL] [Abstract][Full Text] [Related]
20. Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT.
Yue Z; Shusheng J; Hongtao S; Shu Z; Lan H; Qingyuan Z; Shaoqiang C; Yuanxi H
Aging (Albany NY); 2020 Jul; 12(14):14754-14774. PubMed ID: 32716908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
